Free Trial

Repligen Q3 2024 Earnings Report

Repligen logo
$144.46 -2.08 (-1.42%)
(As of 12/20/2024 05:31 PM ET)

Repligen EPS Results

Actual EPS
$0.43
Consensus EPS
$0.34
Beat/Miss
Beat by +$0.09
One Year Ago EPS
$0.23

Repligen Revenue Results

Actual Revenue
$154.87 million
Expected Revenue
$153.34 million
Beat/Miss
Beat by +$1.53 million
YoY Revenue Growth
+9.70%

Repligen Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

Repligen Earnings Headlines

Repligen (NASDAQ:RGEN) Stock Rating Lowered by StockNews.com
Cackling Kamala hates this company
Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.
Repligen Corporation (RGEN) Fell Along with Peers
Repligen (NASDAQ:RGEN) Now Covered by Analysts at Canaccord Genuity Group
BioLife Solutions appoints Hunt to board of directors
See More Repligen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Repligen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Repligen and other key companies, straight to your email.

About Repligen

Repligen (NASDAQ:RGEN) develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

View Repligen Profile

More Earnings Resources from MarketBeat

Upcoming Earnings